← Back to Search

Ultrasound Therapy

ExAblate 4000 - Type 2 for Brain Tumor

N/A
Waitlist Available
Led By Graeme Woodworth, MD
Research Sponsored by InSightec
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the time of the exablate mrgfus procedure
Awards & highlights

Study Summary

This trial is testing a new way to treat brain cancer by temporarily disrupting the blood brain barrier.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the time of the exablate mrgfus procedure and 24 hours post-procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the time of the exablate mrgfus procedure and 24 hours post-procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Device and procedure related adverse events
Secondary outcome measures
Feasibility of BBB disruption

Trial Design

1Treatment groups
Experimental Treatment
Group I: ExAblate 4000 - Type 2Experimental Treatment1 Intervention
ExAblate BBBD

Find a Location

Who is running the clinical trial?

InSightecLead Sponsor
89 Previous Clinical Trials
3,699 Total Patients Enrolled
Graeme Woodworth, MDPrincipal InvestigatorUniversity of Maryland
2 Previous Clinical Trials
140 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Sep 2024